MONROVIA, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) Immunotech Laboratories, Inc. today released the following company updates for shareholders and Investors:
Immunotech Founder, President & Chief Scientific Officer, Harry Zhabilov today stated, "The company plans to release monthly summary progress and status updates to help assure our Investors and shareholders of the forward progression of Immunotech in both the Medical and Investment communities."
Bulgarian Clinical Trials Progress – As of May 1st 2013 IMMB BG subsidiary is absolutely ready with the necessary documentation to start the clinical trials. As of May 15th 2013 they will have signed contracts with the Hospital for Infections - Sofia and Military Hospital - Sofia; afterwards they will start to select 100 patients, who will participate in the clinical trials. The funding, which is required for the project, in the amount of $2, 000, 000 US, is expected to be available by mid June 2013. Additional information about the detailed plan of the clinical trials will be announced shortly.
USA Food & Drug Administration Application Process:
MONROVIA, Calif., Apr. 26, 2013 - Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced the company has initiated the Pre-IND and IND process with the US Food & Drug Administration (FDA). The successful submission of an Investigational New Drug (IND) to FDA will permit Immunotech to conduct clinical trials designed to result in marketing approval for a new drug.
http://finance.yahoo.com/news/immunotech-laboratories-begins-regulatory-process-130000234.html
WORLDWIDE AIDS-HIV CURE UPDATES: Headline: Freya Petersen April 28, 2013 20:51
BREAKING NEWS: HIV cure months away, Danish scientists say, citing novel new DNA treatment
http://www.globalpost.com/dispatch/news/health/130428/hiv-cure-aids-danish-dna-treatment
Further information about Immunotech's patented "IPF"can be obtained from www.immunotechlab.com
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.